New York State Common Retirement Fund raised its stake in Glaukos Corporation (NYSE:GKOS) by 21.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 113,593 shares of the medical instruments supplier’s stock after acquiring an additional 20,219 shares during the quarter. New York State Common Retirement Fund owned approximately 0.33% of Glaukos Corporation worth $4,711,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can purchased a new stake in shares of Glaukos Corporation during the 1st quarter valued at approximately $102,000. BNP Paribas Arbitrage SA lifted its stake in shares of Glaukos Corporation by 740.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,539 shares of the medical instruments supplier’s stock valued at $147,000 after buying an additional 3,118 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of Glaukos Corporation during the 1st quarter valued at approximately $204,000. Caxton Associates LP purchased a new stake in shares of Glaukos Corporation during the 1st quarter valued at approximately $272,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new stake in shares of Glaukos Corporation during the 2nd quarter valued at approximately $262,000. Hedge funds and other institutional investors own 88.95% of the company’s stock.

In other Glaukos Corporation news, Director Orbimed Advisors Llc sold 580,200 shares of Glaukos Corporation stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $38.73, for a total transaction of $22,471,146.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Thomas William Burns sold 73,788 shares of Glaukos Corporation stock in a transaction that occurred on Thursday, September 7th. The shares were sold at an average price of $41.36, for a total transaction of $3,051,871.68. The disclosure for this sale can be found here. In the last three months, insiders sold 980,200 shares of company stock worth $37,900,263. 16.40% of the stock is currently owned by insiders.

A number of analysts recently commented on the stock. BidaskClub upgraded shares of Glaukos Corporation from a “hold” rating to a “buy” rating in a research note on Saturday, June 24th. Cantor Fitzgerald restated a “buy” rating and set a $60.00 price target (up from $54.00) on shares of Glaukos Corporation in a research note on Thursday, September 14th. Zacks Investment Research cut shares of Glaukos Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Roth Capital dropped their price target on shares of Glaukos Corporation from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Thursday, August 3rd. Finally, Piper Jaffray Companies restated a “buy” rating and set a $56.00 price target on shares of Glaukos Corporation in a research note on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Glaukos Corporation currently has a consensus rating of “Buy” and an average target price of $49.86.

COPYRIGHT VIOLATION NOTICE: “Glaukos Corporation (GKOS) Shares Bought by New York State Common Retirement Fund” was posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/10/17/glaukos-corporation-gkos-shares-bought-by-new-york-state-common-retirement-fund.html.

Shares of Glaukos Corporation (GKOS) opened at 32.95 on Tuesday. Glaukos Corporation has a 52 week low of $28.72 and a 52 week high of $52.49. The company’s 50 day moving average is $33.87 and its 200-day moving average is $33.87. The stock’s market capitalization is $1.13 billion.

Glaukos Corporation Profile

Glaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm’s canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream.

Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Corporation (NYSE:GKOS).

Institutional Ownership by Quarter for Glaukos Corporation (NYSE:GKOS)

Receive News & Ratings for Glaukos Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos Corporation and related companies with MarketBeat.com's FREE daily email newsletter.